Copy Link Print Information

Atezolizumab

(Synonyms: MPDL3280A; RG-7446; RO-5541267)
38 Cited Publications
Revisión del cliente

Based on 38 publication(s) in Google Scholar

Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 99.9%
  • No. CAS: 1380723-44-3
  • Peso molecular:144.6 kDa
  • Almacenamiento:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Atezolizumab
  • Experimental Validation Results for Atezolizumab
  • Experimental Validation Results for Atezolizumab
  • Experimental Validation Results for Atezolizumab
  • Experimental Validation Results for Atezolizumab
  • Experimental Validation Results for Atezolizumab
  • Experimental Validation Results for Atezolizumab
  • Experimental Validation Results for Atezolizumab
  • Experimental Validation Results for Atezolizumab
  • Atezolizumab Chemical Structure
    Atezolizumab Chemical Structure
No. CAS: 1380723-44-3
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Atezolizumab Product Recommendations:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Atezolizumab

More
Customer Validation & Images
Histological Imaging/StainingIn Vivo ImagingIn Vivo Efficacy StudyFlow CytometryWB
  • In Vivo Efficacy Study
  • Flow Cytometry
  • WB
  • Histological Imaging/Staining
  • In Vivo Imaging
  • WB
Keywords
100 mg

Obtener un presupuesto En stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG1 kappa

  • 1/16

    Immobilized PD-L1 Protein, Human (HEK293) can bind Atezolizumab. The EC 50 for this effect is 10.9 ng/mL.

  • 1/16

    Flow cytometry analysis of PD-L1 overexpression HEK293 cells labelling PD-L1 with Atezolizumab at 67nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).

  • 1/16

    Atezolizumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

    Customer Validation
     Atezolizumab (4 mg/kg; i.v.) + Bevacizumab (1 mg/kg; i.v.), every other day for 14 days (G4 group) in PDX subcutaneous mouse model. Collected tumor tissues of mice at the end of treatment in different groups.

  • 1/16

    Atezolizumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

    Customer Validation
     Atezolizumab (4mg/kg; i.v.) + Bevacizumab (1mg/kg; i.v.), every other day for 14 days (G4 group) in PDX subcutaneous mouse model. Flow cytometric analysis of anti-CD68/CD206-stained macrophages (gated on CD45+ cells), anti-CD68/CD80-stained macrophages (gated on CD45+ cells),anti-HLA-DR/CD11c-stained DCs (gated on CD45+ Lin-1- T cells), and anti-CD3/CD8-stained T cells (gated on CD45+ cells) in tumor tissues after different treatments (n = 5 independent mice).

  • 1/16

    Atezolizumab purchased from MedChemExpress. Usage Cited in: Nat Nanotechnol. 2025 Feb;20(2):296-302. [Abstract]

    Customer Validation
     PD-L1 expression levels in 293T cells overexpressing PD-L1 after treatment with 500 nM ATZ and ATZ-NPs for 24 h. Vinculin (VINC) was utilized as a loading control.

  • 1/16

    Atezolizumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 May 22:e2309992. [Abstract]

    Customer Validation
     Atezolizumab (100 μg/mouse; i.p.; at days 2, 4, and 6). H&E staining, cleaved-caspase 3, Ki 67, CXCR4 and PD-L1 IHC staining images of tumor slices after various treatments. Group A received PBS. Group B received PBS + ICT (Atezolizumab). Group C received RENPs + ICT. Group D received PBS + RT + ICT. Group E received RENPs + RT + ICT.

  • 1/16

    Atezolizumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 May 22:e2309992. [Abstract]

    Customer Validation
     Atezolizumab (100 μg/mouse; i.p.; at days 2, 4, and 6). Images of mice and excised tumor after different treatments. Group A received PBS. Group B received PBS + ICT (Atezolizumab). Group C received RENPs + ICT. Group D received PBS + RT + ICT. Group E received RENPs + RT + ICT.

  • 1/16

    Atezolizumab purchased from MedChemExpress. Usage Cited in: EJNMMI Res. 2020 Jun 15;10(1):64. [Abstract]

    Customer Validation
     Western blot analysis of total cell lysates using anti-PD-L1 (Atezolizumab, 6.91 nM) and anti-β-actin antibody between LoVo, LS174T, SW620, and RKO in vitro.

  • Atezolizumab Chemical Structure
    1/16
  • Atezolizumab
  • Immobilized PD-L1 Protein, Human (HEK293) can bind Atezolizumab. The EC 50 for this effect is 10.9 ng/mL.
  • Flow cytometry analysis of PD-L1 overexpression HEK293 cells labelling PD-L1 with Atezolizumab at 67nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).